1. Home
  2. WHF vs MSLE Comparison

WHF vs MSLE Comparison

Compare WHF & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WHF

WhiteHorse Finance Inc.

HOLD

Current Price

$7.63

Market Cap

164.5M

Sector

Finance

ML Signal

HOLD

MSLE

Satellos Bioscience Inc. Common Stock

N/A

Current Price

$7.81

Market Cap

146.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
WHF
MSLE
Founded
2011
N/A
Country
United States
Canada
Employees
3
17
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
164.5M
146.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WHF
MSLE
Price
$7.63
$7.81
Analyst Decision
Sell
Analyst Count
2
0
Target Price
$7.75
N/A
AVG Volume (30 Days)
79.4K
54.6K
Earning Date
05-07-2026
N/A
Dividend Yield
13.67%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.07
$5.50
52 Week High
$9.68
$13.39

Technical Indicators

Market Signals
Indicator
WHF
MSLE
Relative Strength Index (RSI) 57.63 53.56
Support Level $6.80 $6.73
Resistance Level $7.83 $8.37
Average True Range (ATR) 0.14 0.79
MACD -0.02 0.14
Stochastic Oscillator 51.43 48.56

Price Performance

Historical Comparison
WHF
MSLE

About WHF WhiteHorse Finance Inc.

WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.

About MSLE Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Share on Social Networks: